Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Faron Pharmaceuticals Oy    FARN   FI4000153309

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote London Stock Exchange
09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
865(c) 865(c) 840(c) 822.5(c) 822.5 Last
0 150 3 365 0 0 Volume
+4.22% 0.00% -2.89% -2.08% -2.08% Change
More quotes
Financials ( GBP)
Sales 2017 0,38 M
EBIT 2017 -12,1 M
Net income 2017 -12,9 M
Finance 2017 3,20 M
Yield 2017 -
Sales 2018 3,06 M
EBIT 2018 -13,3 M
Net income 2018 -13,8 M
Debt 2018 10,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 606x
EV / Sales2018 79,0x
Capitalization 231 M
More Financials
Company
Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development.The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage.It operates through the Traumakine and Clevegen brands for acute respiratory... 
More about the company
Latest news on FARON PHARMACEUTICALS OY
09/14 FARON PHARMACEUTICALS OY : Director's Dealing
09/11 FARON PHARMACEUTICALS OY : Ltd - Interim Results for the six months ended 30 Jun..
09/07 FARON PHARMACEUTICALS OY : FDA advises Faron to proceed directly to BLA
09/06 FARON PHARMACEUTICALS OY : Interim Results for the six months ended 30 June 2017
09/04 FARON PHARMACEUTICALS OY : Faron announces that US FDA proposes proceeding direc..
09/01FARON PHARMACEUTICALS OY : half-yearly earnings release
08/04 FARON PHARMACEUTICALS OY : Update on INTEREST Phase III Study from IDMC
07/10 FARON PHARMACEUTICALS OY : Notice of Results
06/01 FARON PHARMACEUTICALS OY : Exercise of Warrants and Options Issue of Equity
05/16 FARON PHARMACEUTICALS OY : Results of the Annual General Meeting and Decisions o..
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/06Faron Pharmaceuticals Oy: Interim Results for the six months ended 30 June 20.. 
09/06Faron Pharmaceuticals Oy's buy rating reiterated at Panmure Gordon.  
09/04Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding dir.. 
09/04Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding dir.. 
09/04Faron Pharmaceuticals Oy: Faron announces that US FDA proposes proceeding dir.. 
More tweets
Qtime:7
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | 4-Traders
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,23  GBP
Spread / Average Target -12%
Managers
NameTitle
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Frank Murdoch Armstrong Non-Executive Chairman
Mikael Maksimow Vice President-Operations
Yrjö Erik Kristian Wichmann Chief Financial Officer & Executive Director
Matti Karvonen Chief Medical Officer & VP-Drug Development
Sector and Competitors
1st jan.Capitalization (M$)
FARON PHARMACEUTICALS OY216.98%312
AMGEN28.70%135 544
CELGENE CORPORATION24.61%112 572
GILEAD SCIENCES15.40%108 744
REGENERON PHARMACEUTICALS19.36%46 367
VERTEX PHARMACEUTICALS107.30%38 136